<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554540</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC TIPPS 11 18</org_study_id>
    <nct_id>NCT01554540</nct_id>
  </id_info>
  <brief_title>Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study</brief_title>
  <acronym>TIPPS</acronym>
  <official_title>Pharmacodynamic and Pharmacokinetic Assessment of Treprostinil Iontophoresis on the Forearm and the Fingers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess skin blood flow after non-invasive local administration
      of treprostinil by using a low-intensity current (i.e. iontophoresis) on the forearm and the
      fingers of healthy volunteers and patients with systemic sclerosis. The investigators also
      aim at assessing the systemic bioavailability and dermal diffusion of treprostinil
      iontophoresis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Digital ulcerations are a complication of systemic sclerosis (SSc). Available treatments
      (i.e. IV iloprost) induce major adverse effects, limiting the use of such therapies.
      Iontophoresis is a non invasive route of administration of drugs. In experimental and
      clinical preliminary studies, the investigators have shown that iontophoresis of treprostinil
      on the forearm of healthy subjects induces a sustained increase in skin blood flux and that
      it is well tolerated (clinicaltrials.gov NCT01082484, manuscript in press). The investigators
      therefore aim at validating this proof of concept on the digits of SSc patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of cutaneous blood flow</measure>
    <time_frame>0, 15min, 30 min, 1h, 2h, 4h, 6h, 8h, 10h</time_frame>
    <description>Cutaneous blood flow assessed with Laser Speckle Contrast Imaging (LSCI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treprostinil blood concentration</measure>
    <time_frame>0, 15min, 30 min, 1h, 2h, 4h, 6h, 8h, 10h</time_frame>
    <description>AUC of treprostinil concentration from the end of iontophoresis until 10 hours after iontophoresis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treprostinil dermal concentration</measure>
    <time_frame>1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h</time_frame>
    <description>AUC of treprostinil concentration in the dermis (collected with microdialysis) from the end of iontophoresis until 10 hours after iontophoresis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>Cutaneous iontophoresis of Treprostenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous iontophoresis of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cutaneous iontophoresis of treprostinil</intervention_name>
    <description>Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).</description>
    <arm_group_label>Cutaneous iontophoresis of Treprostenil</arm_group_label>
    <arm_group_label>Cutaneous iontophoresis of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cutaneous systemic scleroderma with sclerosed fingers

        Exclusion Criteria:

          -  pregnant or breast-feeding women

          -  any chronic disease (in the control group)

          -  smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Cracowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM 003</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC pharmacology - University Hopsital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Blaise S, Roustit M, Millet C, Ribuot C, Boutonnat J, Cracowski JL. Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats. Br J Pharmacol. 2011 Feb;162(3):557-65. doi: 10.1111/j.1476-5381.2010.01045.x.</citation>
    <PMID>20860718</PMID>
  </reference>
  <reference>
    <citation>Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci. 2006 Sep;27(9):503-8. Epub 2006 Jul 31. Review.</citation>
    <PMID>16876881</PMID>
  </reference>
  <reference>
    <citation>Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000 Nov;12(6):527-33. Review.</citation>
    <PMID>11092203</PMID>
  </reference>
  <reference>
    <citation>Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004 Mar 27;56(5):619-58. Review.</citation>
    <PMID>15019750</PMID>
  </reference>
  <reference>
    <citation>Murray AK, Moore TL, King TA, Herrick AL. Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis? Rheumatology (Oxford). 2008 Jan;47(1):76-9.</citation>
    <PMID>18077494</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treprostinil</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Iontophoresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

